Gunderson Dettmer represented client TScan Therapeutics, a biotechnology company developing immunotherapy treatments for cancer, in its $100 million Series C financing. The new funding will be used to advance TScan’s TCR-T cell therapy pipeline for solid and liquid tumors into the clinic.

In the announcement of the transaction, CEO of TScan David Southwell said, “I’m excited to welcome this new syndicate of distinguished healthcare investors to TScan. Recently, we have identified over 40 novel cancer targets from clinically active TCRs for development of multiplexed TCR-T cell therapies as part of our solid tumor program. Our goal is to continue to build a bank of clinically-active TCRs throughout 2021 to help patients win their fight against cancer.”

The Gunderson deal team was led by Tim Ehrlich and included Brendan McCarthy, Keith Scherer, Andrew Weymouth, George Pothoulakis, Ademisola Ijidakinro and Alice Kuo.